Reference Detail


Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at :

Ref Type
Authors Stefan D. Gross, R. Xu, M. Boys, K. Condroski, L. DeMeese, W.E. DeWolf, B. Fell, J. Fischer, S. Gloor, M. J. Humphries, G. Miknis, K. Regal, M.Rodriguez, N. Raddatz, K. Shotts, G. Topalov, E. Wallace, J. Zuzack, J. A. Josey, J. Winkler, Kevin Koch
Title Abstract 4484: AR-mTOR-26 - A potent, selective mTORC 1/2 kinase inhibitor for the treatment of malignancy
Abstract Text for oncology.


  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")


  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Molecular Profile Treatment Approach
Gene Name Source Synonyms Protein Domains Gene Description Gene Role
Therapy Name Drugs Efficacy Evidence Clinical Trials
AR-mTOR-26 AR-mTOR-26 1 0
Drug Name Trade Name Synonyms Drug Classes Drug Description
AR-mTOR-26 AR mTOR 26 mTOR Inhibitor 51 AR-mTOR-26 is a selective inhibitor of mTOR, which leads to decreased signaling through mTORC1 and mTORC2, and may lead to decreased tumor growth (Cancer Res April 15, 2010 70; 4484, PMID: 20024839).
Gene Variant Impact Protein Effect Variant Description Associated with drug Resistance
Molecular Profile Indication/Tumor Type Response Type Therapy Name Approval Status Evidence Type Efficacy Evidence References
PTEN loss prostate cancer predicted - sensitive AR-mTOR-26 Preclinical - Cell line xenograft Actionable In a preclinical study, AR-mTOR-26 treatment resulted in antitumor activity in prostate cancer xenograft models with PTEN loss (Cancer Res 2010;70(8 Suppl):Abstract nr 4484). detail...